Nippon India Pharma Fund Datagrid
Category Pharma Fund
BMSMONEY Rank -
Rating
Growth Option 16-11-2026
NAV ₹585.1(R) -0.02% ₹659.36(D) -0.02%
Returns 1Y 3Y 5Y 7Y 10Y
Lumpsum Regular 12.27% 17.12% 13.94% 21.69% 15.63%
Direct 13.25% 18.17% 14.97% 22.78% 16.66%
Benchmark
SIP (XIRR) Regular 20.37% 12.38% 16.88% 17.52% 17.85%
Direct 21.39% 13.37% 17.94% 18.59% 18.9%
Ratio Sharpe Ratio Sortino Ratio Sterling Ratio Jensen's Alpha Treynor Ratio
0.94 0.48 0.86 0.44% 0.17
Risk STD. Dev VaR 1Y95% Max DD Beta Semi Devi.
15.33% -17.95% -14.28% 0.88 11.06%
Fund AUM As on: 30/12/2025 8349 Cr

NAV Date: 16-11-2026

Scheme Name NAV Rupee Change Percent Change
NIPPON INDIA PHARMA FUND - IDCW Option 126.35
-0.0300
-0.0200%
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option 180.45
-0.0300
-0.0200%
Nippon India Pharma Fund-Growth Plan-Growth Option 585.1
-0.1400
-0.0200%
Nippon India Pharma Fund-Growth Plan-Bonus Option 585.1
-0.1400
-0.0200%
Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option 659.36
-0.1200
-0.0200%
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option 659.36
-0.1200
-0.0200%

Review Date: 16-11-2026

Beginning of Analysis

The Nippon India Pharma Fund has shown a very good past performence in Pharma Fund. The Nippon India Pharma Fund has a Jensen Alpha of 0.44% which is lower than the category average of 1.66%, showing poor performance. The Nippon India Pharma Fund has a Sharpe Ratio of 0.94 which is lower than the category average of 1.04, showing poor performance.
The past performance of the {fund_name_eng} may or may not be sustained in the future. The review is not investment advice nor is it a recommendation to buy or sell funds.
Pharma Mutual Funds

Nippon India Pharma Fund Return Analysis

The Nippon India Pharma Fund has delivered a mixed performance across various time horizons, showcasing both strengths and challenges when compared to its Pharma Fund peers and the Nifty Pharma TRI benchmark. This analysis examines the fund’s returns over periods ranging from one month to ten years, alongside its Systematic Investment Plan (SIP) performance, highlighting its rankings within the Pharma Fund category and its ability to outperform or underperform the benchmark and category averages.

  • The fund has given a return of 9.11%, 2.78 and 7.55 in last one, three and six months respectively. In the same period the category average return was 8.92%, 3.38% and 13.5% respectively.
  • Nippon India Pharma Fund has given a return of 13.25% in last one year. In the same period the Nifty Pharma TRI return was 19.04%. The fund has given 5.79% less return than the benchmark return.
  • The fund has given a return of 18.17% in last three years and rank 11th out of eleven funds in the category. In the same period the Nifty Pharma TRI return was 20.47%. The fund has given 2.3% less return than the benchmark return.
  • Nippon India Pharma Fund has given a return of 14.97% in last five years and category average returns is 16.98% in same period. The fund ranked 8.0th out of eight funds in the category. In the same period the Nifty Pharma TRI return was 14.46%. The fund has given 0.51% more return than the benchmark return.
  • The fund has given a return of 16.66% in last ten years and ranked 1.0st out of four funds in the category. In the same period the Nifty Pharma TRI return was 9.3%. The fund has given 7.36% more return than the benchmark return.
  • The fund has given a SIP return of 21.39% in last one year whereas category average SIP return is 30.01%. The fund one year return rank in the category is 13th in 16 funds
  • The fund has SIP return of 13.37% in last three years and ranks 9th in 11 funds. HDFC Pharma And Healthcare Fund has given the highest SIP return (27.01%) in the category in last three years.
  • The fund has SIP return of 17.94% in last five years whereas category average SIP return is 20.39%.

Nippon India Pharma Fund Risk Analysis

  • The fund has a standard deviation of 15.33 and semi deviation of 11.06. The category average standard deviation is 15.94 and semi deviation is 11.38.
  • The fund has a Value at Risk (VaR) of -17.95 and a maximum drawdown of -14.28. The category average VaR is -18.94 and the maximum drawdown is -14.76. The fund has a beta of 0.87 which shows that fund is less volatile than the benchmark.

Standard deviation measures the fund's return volatility and Semi deviation focuses on downside volatility. Value at Risk (VaR) is a measure of the risk of investments. Maximum Drawdown is the maximum loss from a peak to a trough of a portfolio. Beta measures the volatility of the fund compared to the benchmark. A beta of 1 indicates that the fund will move in line with the benchmark. A beta of more than 1 indicates that the fund will be more volatile than the benchmark and vice versa.


  • Very Good Performance in Pharma Fund Category
  • Good Performance in Pharma Fund Category
  • Poor Performance in Pharma Fund Category
  • Very Poor Performance in Pharma Fund Category

  • Investors beware: Mutual Fund investments are subject to market risks. Please read the scheme related documents carefully.

    Data Source: www.amfiindia.com

    SEBI Categorization


    KPIs* Fund Benchmark Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % 9.03 9.01
    8.80
    5.53 | 10.56 10 | 17 Good
    3M Return % 2.56 6.70
    3.04
    -0.27 | 6.75 10 | 17 Good
    6M Return % 7.10 13.89
    12.76
    5.60 | 18.92 15 | 17 Average
    1Y Return % 12.27 23.62
    18.84
    8.14 | 29.71 14 | 16 Poor
    3Y Return % 17.12 22.35
    20.85
    16.84 | 29.38 10 | 11 Poor
    5Y Return % 13.94 16.13
    15.60
    13.83 | 19.01 7 | 8 Poor
    7Y Return % 21.69 20.92
    22.58
    19.88 | 24.37 6 | 8 Average
    10Y Return % 15.63 11.05
    14.96
    14.30 | 15.63 1 | 4 Very Good
    15Y Return % 17.34 13.50
    17.07
    15.74 | 18.13 2 | 3 Good
    1Y SIP Return % 20.37
    28.31
    8.17 | 42.99 13 | 16 Poor
    3Y SIP Return % 12.38
    15.78
    10.41 | 25.56 9 | 11 Average
    5Y SIP Return % 16.88
    18.98
    15.82 | 22.45 7 | 8 Poor
    7Y SIP Return % 17.52
    18.98
    16.60 | 21.70 6 | 8 Average
    10Y SIP Return % 17.85
    18.25
    16.74 | 19.77 3 | 4 Average
    15Y SIP Return % 16.62
    16.50
    15.87 | 17.01 2 | 3 Good
    Standard Deviation 15.33
    15.95
    14.65 | 16.87 2 | 8 Very Good
    Semi Deviation 11.06
    11.39
    10.68 | 12.13 4 | 8 Good
    Max Drawdown % -14.28
    -14.76
    -16.36 | -12.33 3 | 8 Good
    VaR 1 Y % -17.95
    -18.95
    -23.32 | -15.67 3 | 8 Good
    Average Drawdown % 5.68
    5.47
    3.66 | 6.79 4 | 8 Good
    Sharpe Ratio 0.94
    1.04
    0.87 | 1.20 7 | 8 Poor
    Sterling Ratio 0.86
    0.94
    0.81 | 1.09 7 | 8 Poor
    Sortino Ratio 0.48
    0.54
    0.44 | 0.63 7 | 8 Poor
    Jensen Alpha % 0.44
    1.66
    -0.46 | 3.84 5 | 8 Average
    Treynor Ratio 0.17
    0.20
    0.16 | 0.23 7 | 8 Poor
    Modigliani Square Measure % 15.52
    17.20
    14.35 | 19.86 7 | 8 Poor
    Alpha % -1.73
    0.06
    -1.73 | 3.02 8 | 8 Poor
    Return data last Updated On : Nov. 16, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : June 30, 2026
    KPIs: Key Performance Indicators

    Rotate the phone! Best viewed in landscape mode on mobile.
    KPIs* Fund Benchmark Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % 9.11 9.01 8.92 5.67 | 10.65 10 | 17 Good
    3M Return % 2.78 6.70 3.38 0.07 | 7.15 11 | 17 Average
    6M Return % 7.55 13.89 13.50 6.24 | 19.83 15 | 17 Average
    1Y Return % 13.25 23.62 20.44 9.37 | 31.76 14 | 16 Poor
    3Y Return % 18.17 22.35 22.32 18.17 | 30.91 11 | 11 Poor
    5Y Return % 14.97 16.13 16.98 14.97 | 20.26 8 | 8 Poor
    7Y Return % 22.78 20.92 24.08 21.67 | 26.12 6 | 8 Average
    10Y Return % 16.66 11.05 16.27 16.08 | 16.66 1 | 4 Very Good
    1Y SIP Return % 21.39 30.01 9.57 | 45.19 13 | 16 Poor
    3Y SIP Return % 13.37 17.18 12.03 | 27.01 9 | 11 Average
    5Y SIP Return % 17.94 20.39 17.57 | 23.72 7 | 8 Poor
    7Y SIP Return % 18.59 20.42 18.37 | 22.99 7 | 8 Poor
    10Y SIP Return % 18.90 19.56 18.51 | 21.01 3 | 4 Average
    Standard Deviation 15.33 15.95 14.65 | 16.87 2 | 8 Very Good
    Semi Deviation 11.06 11.39 10.68 | 12.13 4 | 8 Good
    Max Drawdown % -14.28 -14.76 -16.36 | -12.33 3 | 8 Good
    VaR 1 Y % -17.95 -18.95 -23.32 | -15.67 3 | 8 Good
    Average Drawdown % 5.68 5.47 3.66 | 6.79 4 | 8 Good
    Sharpe Ratio 0.94 1.04 0.87 | 1.20 7 | 8 Poor
    Sterling Ratio 0.86 0.94 0.81 | 1.09 7 | 8 Poor
    Sortino Ratio 0.48 0.54 0.44 | 0.63 7 | 8 Poor
    Jensen Alpha % 0.44 1.66 -0.46 | 3.84 5 | 8 Average
    Treynor Ratio 0.17 0.20 0.16 | 0.23 7 | 8 Poor
    Modigliani Square Measure % 15.52 17.20 14.35 | 19.86 7 | 8 Poor
    Alpha % -1.73 0.06 -1.73 | 3.02 8 | 8 Poor
    Return data last Updated On : Nov. 16, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : June 30, 2026
    KPIs: Key Performance Indicators

    Disclaimer: Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments. Returns for periods above 1 year are annualised.


    Date Nippon India Pharma Fund NAV Regular Growth Nippon India Pharma Fund NAV Direct Growth
    16-11-2026 585.1034 659.3613
    13-11-2026 585.2465 659.4767
    12-11-2026 586.6782 661.0746
    11-11-2026 588.5087 663.1218
    09-11-2026 588.1467 662.683
    06-11-2026 574.0981 646.809
    05-11-2026 568.9138 640.9532
    04-11-2026 566.9412 638.7159
    03-11-2026 561.4642 632.5308
    02-11-2026 557.6364 628.2039
    30-10-2026 555.2364 625.4566
    29-10-2026 552.3717 622.2151
    28-10-2026 550.4816 620.0717
    27-10-2026 542.844 611.4543
    26-10-2026 533.473 600.885
    23-10-2026 524.8618 591.1445
    22-10-2026 527.8479 594.4939
    21-10-2026 528.6359 595.3675
    19-10-2026 531.1304 598.1491
    16-10-2026 536.6384 604.31

    Fund Launch Date: 10/May/2004
    Fund Category: Pharma Fund
    Investment Objective: The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years
    Fund Description: An open ended equity scheme investing in pharma sector
    Fund Benchmark: S&P BSE Healthcare TR
    Source: Fund FactSheet

    Disclaimer: NO INVESTMENT ADVICE. The Content is for informational purposes only.